Search Results - "Konishi, Jun Sakakibara"

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail by Furuta, Megumi, Kikuchi, Hajime, Shoji, Tetsuaki, Takashima, Yuta, Kikuchi, Eiki, Kikuchi, Junko, Kinoshita, Ichiro, Dosaka‐Akita, Hirotoshi, Sakakibara‐Konishi, Jun

“…Delta‐like protein 3 (DLL3) is a ligand of Notch signaling, which mediates cell‐fate decisions and is tumor‐suppressive or oncogenic depending on the cellular…”
Get full text

Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR‐mutated non–small‐cell lung cancer by Takahashi, Hirofumi, Sakakibara‐Konishi, Jun, Furuta, Megumi, Shoji, Tetsuaki, Tsuji, Kosuke, Morinaga, Daisuke, Kikuchi, Eiki, Kikuchi, Junko, Noguchi, Takuro, Hatanaka, Kanako C., Hatanaka, Yutaka, Shinagawa, Naofumi, Konno, Satoshi

“…Osimertinib is a third‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients…”
Get full text

Bromodomain and extraterminal domain inhibition synergizes with WEE1‐inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer by Takashima, Yuta, Kikuchi, Eiki, Kikuchi, Junko, Suzuki, Motofumi, Kikuchi, Hajime, Maeda, Makie, Shoji, Tetsuaki, Furuta, Megumi, Kinoshita, Ichiro, Dosaka‐Akita, Hirotoshi, Sakakibara‐Konishi, Jun, Konno, Satoshi

“…Bromodomain and extraterminal domain (BET) inhibitors are broadly active against distinct types of cancer, including nonsmall cell lung cancer (NSCLC)…”
Get full text

EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment by Shiiya, Akihiko, Noguchi, Takuro, Tomaru, Utano, Ariga, Shin, Takashima, Yuta, Ohhara, Yoshihito, Taguchi, Jun, Takeuchi, Satoshi, Shimizu, Yasushi, Kinoshita, Ichiro, Koizumi, Tomonobu, Matsuno, Yoshihiro, Shinagawa, Naofumi, Sakakibara‐Konishi, Jun, Dosaka‐Akita, Hirotoshi

“…Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR‐mutant non–small‐cell lung cancer (NSCLC)…”
Get full text

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study by Seto, Takashi, Hayashi, Hidetoshi, Satouchi, Miyako, Goto, Yasushi, Niho, Seiji, Nogami, Naoyuki, Hida, Toyoaki, Takahashi, Toshiaki, Sakakibara‐Konishi, Jun, Morise, Masahiro, Nagasawa, Takashi, Suzuki, Mie, Ohkura, Masayuki, Fukuhara, Kei, Thurm, Holger, Peltz, Gerson, Nishio, Makoto

“…Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is…”
Get full text

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan by Kitagataya, Takashi, Suda, Goki, Nagashima, Kazunori, Katsurada, Takehiko, Yamamoto, Koji, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, Komatsu, Yoshito, Hata, Hiroo, Takeuchi, Satoshi, Abe, Takashige, Sakakibara‐Konishi, Jun, Teshima, Takanori, Homma, Akihiro, Sakamoto, Naoya

“…Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti‐malignancy therapy and thus have been increasingly used. Although ICI may cause…”
Get full text

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells by Takashina, Taichi, Kinoshita, Ichiro, Kikuchi, Junko, Shimizu, Yasushi, Sakakibara‐Konishi, Jun, Oizumi, Satoshi, Nishimura, Masaharu, Dosaka‐Akita, Hirotoshi

“…Recent discoveries have revealed that human cancer involves aberrant epigenetic alterations. We and others have previously shown that the histone…”
Get full text

Drop finger caused by lung cancer metastasis by Sumi, Toshiyuki, Sakakibara‐Konishi, Jun, Suzuki, Keito, Chiba, Hirofumi

“…Skeletal muscle metastasis of lung cancer is rare. However, clinicians should be aware that tumour‐induced nerve compression symptoms may develop. We present a…”
Get full text

Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy by Sato, Mineyoshi, Maishi, Nako, Hida, Yasuhiro, Yanagawa‐Matsuda, Aya, Alam, Mohammad Towfik, Sakakibara‐Konishi, Jun, Nam, Jin‐Min, Onodera, Yasuhito, Konno, Satoshi, Hida, Kyoko

“…In lung cancer, immune checkpoint inhibitors (ICIs) are often inadequate for tumor growth inhibition. Angiogenic inhibitors (AIs) are required to normalize…”
Get full text

Immune checkpoint inhibitor‐induced enteritis assessed using capsule endoscopy by Otagiri, Shinsuke, Katsurada, Takehiko, Yamanashi, Kana, Sakurai, Kensuke, Sato, Michiko T, Sakakibara‐Konishi, Jun, Sakamoto, Naoya

“…We performed capsule endoscopy for a patient with immune checkpoint inhibitor‐induced enteritis and found multiple erosions or small ulcers in the small…”
Get full text

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage by Shoji, Tetsuaki, Mizugaki, Hidenori, Ikezawa, Yasuyuki, Furuta, Megumi, Takashima, Yuta, Kikuchi, Hajime, Goudarzi, Houman, Asahina, Hajime, Kikuchi, Junko, Kikuchi, Eiki, Sakakibara-Konishi, Jun, Shinagawa, Naofumi, Tsujino, Ichizo, Nishimura, Masaharu

“…This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was…”
Get full text

Expression of Bim, Noxa, and Puma in non-small cell lung cancer by Sakakibara-Konishi, Jun, Oizumi, Satoshi, Kikuchi, Junko, Kikuchi, Eiki, Mizugaki, Hidenori, Kinoshita, Ichiro, Dosaka-Akita, Hirotoshi, Nishimura, Masaharu

“…The BH3-only members of the Bcl-2 protein family have been proposed to play a key role in the control of apoptosis and in the initiation of the apoptotic…”
Get full text

Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment by Saito, Yoshitaka, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru

“…Docetaxel (DOC) and ramucirumab (RAM) is one of the most effective regimens for advanced non-small cell lung cancer (NSCLC) treatment. In our previous study,…”
Get full text

A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid) by Sugimoto, Akira, Matsumoto, Shingo, Udagawa, Hibiki, Itotani, Ryo, Usui, Yuko, Umemura, Shigeki, Nishino, Kazumi, Nakachi, Ichiro, Kuyama, Shoichi, Daga, Haruko, Hara, Satoshi, Miyamoto, Shingo, Kato, Terufumi, Sakakibara-Konishi, Jun, Tabata, Eriko, Nakagawa, Taku, Kawaguchi, Tomoya, Sakai, Tetsuya, Shibata, Yuji, Izumi, Hiroki, Nosaki, Kaname, Zenke, Yoshitaka, Yoh, Kiyotaka, Goto, Koichi

“…We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non-small cell lung cancer…”
Get full text

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702) by Furuta, Megumi, Sakakibara‐Konishi, Jun, Kikuchi, Hajime, Yokouchi, Hiroshi, Nishihara, Hiroshi, Minemura, Hiroyuki, Harada, Masao, Yamazaki, Shigeo, Akie, Kenji, Fujita, Yuka, Takamura, Kei, Kojima, Tetsuya, Harada, Toshiyuki, Minami, Yoshinori, Watanabe, Naomi, Oizumi, Satoshi, Suzuki, Hiroyuki, Nishimura, Masaharu, Dosaka‐Akita, Hirotoshi, Isobe, Hiroshi

“…Background Delta‐like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently,…”
Get full text

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer by Izumi, Hiroki, Matsumoto, Shingo, Liu, Jie, Tanaka, Kosuke, Mori, Shunta, Hayashi, Kumiko, Kumagai, Shogo, Shibata, Yuji, Hayashida, Takuma, Watanabe, Kana, Fukuhara, Tatsuro, Ikeda, Takaya, Yoh, Kiyotaka, Kato, Terufumi, Nishino, Kazumi, Nakamura, Atsushi, Nakachi, Ichiro, Kuyama, Shoichi, Furuya, Naoki, Sakakibara-Konishi, Jun, Okamoto, Isamu, Taima, Kageaki, Ebi, Noriyuki, Daga, Haruko, Yamasaki, Akira, Kodani, Masahiro, Udagawa, Hibiki, Kirita, Keisuke, Zenke, Yoshitaka, Nosaki, Kaname, Sugiyama, Eri, Sakai, Tetsuya, Nakai, Tokiko, Ishii, Genichiro, Niho, Seiji, Ohtsu, Atsushi, Kobayashi, Susumu S., Goto, Koichi

“…Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in…”
Get full text

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer by Yasuda, Hiroyuki, Ichihara, Eiki, Sakakibara-Konishi, Jun, Zenke, Yoshitaka, Takeuchi, Shinji, Morise, Masahiro, Hotta, Katsuyuki, Sato, Mineyoshi, Matsumoto, Shingo, Tanimoto, Azusa, Matsuzawa, Reiko, Kiura, Katuyuki, Takashima, Yuta, Yano, Seiji, Koyama, Junji, Fukushima, Takahiro, Hamamoto, Junko, Terai, Hideki, Ikemura, Shinnosuke, Takemura, Ryo, Goto, Koichi, Soejima, Kenzo

“…•Osimertinib 80 mg showed limited efficacy for NSCLC with EGFR ex20ins mutations.•The mutation type-specific concentration-dependency of osimertinibwas…”
Get full text

Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy by Sakamoto, Tatsuhiko, Kado, Moeko, Saito, Yoshitaka, Uchiyama, Kazuki, Kanno, Ryota, Taniguchi, Osamu, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru

“…Although carboplatin (CBDCA) is classified as a moderately emetogenic agent, the majority of guidelines recommend the use of a neurokinin-1 receptor antagonist…”
Get full text

Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment by Saito, Yoshitaka, Tamaki, Shinya, Hirate, Daisuke, Takada, Shinya, Takahashi, Kenta, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru

“…Treatment using docetaxel (DOC) and ramucirumab (RAM) is an effective regimen in second or later line advanced non-small cell lung carcinoma (NSCLC) treatment…”
Get full text

Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients by Saito, Yoshitaka, Kobayashi, Masaki, Tamaki, Shinya, Nakamura, Katsuyuki, Hirate, Daisuke, Takahashi, Kenta, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru

“…The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline…”
Get full text